Highlights
1 patentProfile claimed by owner
About
Ophthalmic Drug Delivery
Eximore is developing ophthalmic drug-delivery products. The company's initial target is a noninvasive punctal plug designed to release glaucoma drugs, controlled over a long period of time. Eximore's product aims to circumvent the need to apply daily eye drops and thereby improve compliance.
Identity
| Name | Eximore |
|---|---|
| Slug | eximore |
| Type / kind | startup |
| Crunchbase ID | eximore |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN6uzYUIDA |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ city | Shoham |
| HQ address | HaBsor St 49, Shoham, Israel |
Web & social
| Website | https://eximore.co.il/ |
|---|
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug DeliveryMedical DevicesMedical Treatment & Therapeutics
Technologies
Materials & Substances
Target customers
Healthcare & Life SciencesHealthcareProviders
Business models
B2CB2B
Tags
bioconvergencepersonalizationnon-invasiveeye-diseasesmedical-technologiesdrug-deliveryophthalmologyglaucomamedical-devicesadherenceclinicsbiopharmaceutical
Funding
| Total raised | $3.6M |
|---|---|
| Current stage | Series A |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}